| abstract |
The present invention relates to oligomer compounds (oligomers) which target osteopontin mRNA in a cell, leading to reduced expression of osteopontin. Reduction of osteopontin expression is beneficial for the treatment of diseases or disorders associated with overexpression or undesirably high levels of osteopontin, such as ischemia/reperfusion injury, e.g., after organ transplantation, such as renal transplantation. |